# Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

> **NCT06892054** · PHASE1 · RECRUITING · sponsor: **Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)** · enrollment: 15 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

## Key facts

- **NCT ID:** NCT06892054
- **Lead sponsor:** Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-08
- **Primary completion:** 2030-08-08
- **Final completion:** 2030-08-08
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- Apices Soluciones S.L.
- GERCOR - Multidisciplinary Oncology Cooperative Group

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892054, "Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT06892054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*